TRML Tourmaline Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TRML

Price (delayed)

$15.84

Market cap

$406.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.87

Enterprise value

$265.7M

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic ...

Highlights
The quick ratio has soared by 124% from the previous quarter
TRML's EPS has surged by 61% year-on-year and by 55% since the previous quarter
Tourmaline Bio's net income has shrunk by 114% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://talaristx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TRML
Market
Shares outstanding
25.65M
Market cap
$406.24M
Enterprise value
$265.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$42.12M
EBITDA
-$41.97M
Free cash flow
-$28.14M
Per share
EPS
-$8.87
Free cash flow per share
-$5.93
Book value per share
$10.08
Revenue per share
$0
TBVPS
$44.3
Balance sheet
Total assets
$210.3M
Total liabilities
$5.25M
Debt
$415,000
Equity
$205.04M
Working capital
$203.87M
Liquidity
Debt to equity
0
Current ratio
41.76
Quick ratio
40.62
Net debt/EBITDA
3.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-24.3%
Return on equity
-25.6%
Return on invested capital
-40.9%
Return on capital employed
-20.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TRML stock price

How has the Tourmaline Bio stock price performed over time
Intraday
-0.5%
1 week
1.02%
1 month
-27.67%
1 year
-43.43%
YTD
-39.5%
QTD
-30.83%

Financial performance

How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.41M
Net income
-$42.12M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's operating income has plunged by 130% YoY
Tourmaline Bio's net income has shrunk by 114% YoY

Growth

What is Tourmaline Bio's growth rate over time

Valuation

What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
1.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has surged by 61% year-on-year and by 55% since the previous quarter
TRML's equity is up by 44% since the previous quarter
The price to book (P/B) is 31% higher than the last 4 quarters average of 1.2

Efficiency

How efficient is Tourmaline Bio business performance
The company's return on assets has shrunk by 108% YoY
Tourmaline Bio's ROE has plunged by 98% YoY

Dividends

What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRML.

Financial health

How did Tourmaline Bio financials performed over time
The quick ratio has soared by 124% from the previous quarter
Tourmaline Bio's current ratio has surged by 124% QoQ
The company's debt is 100% lower than its equity
The company's debt to equity has surged by 100% YoY
TRML's equity is up by 44% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.